Pharma company Mylan launched COVID-19 drug in the market, know how much it costs

HIGHLIGHTS: Due to high demand, the drug was being sold at a price up to 10 times the fixed price in black market.

From today, another company Mylan's Remdesivir medicine has come in the market. This drug is used in CORONA and is in great demand. The company has launched it in the market at a price of Rs. 4,800/-. Earlier, Hetero's Remdesivir has come on the market at a price of Rs 5,400/- and Cipla's Remdesivir at Rs 4,000/-. There is a black market due to the huge demand for Remdesivir. This drug was being sold at a price up to 10 times the fixed price. It is believed that due to increase in supply of other companies, there will be a decrease in black market.

In recent times, drug controllers of Maharashtra and Gujarat have initiated action by registering cases against many people. A committee has also been formed in Gujarat to monitor the medicine. The central government has also asked companies to start helpline numbers in view of people's problems. Where you can find out about the supply of needy medicine and can tell your need. Actually, this drug is being effective to some extent in the treatment of COVID-19. In such a situation, doctors are writing prescription.

Medicines will be cheaper by themselves

According to sources, the pricing regulator believes that in the coming times, prices will automatically come down due to increasing competition among pharmaceutical companies. An advisory can be issued to reduce the drug prices if required at the most. Then the regulator can ask for the details of the cost and supply of the pharmaceutical companies. However, till now information about this has not been sought from any company.

NPPA may regulate price

The NPPA had also issued a similar advisory regarding N-95 masks, after which the prices started falling. In fact, many medicines used in Remdesivir and COVID-19 are outside the scope of price control. However, under Para 19 in Drug Price Control Order 2013, NPPA can fix the price of any drug i.e. drug and medical device which has fallen into the category of drug. The NPPA had drastically cut stent prices under this right. Later, the prices of orthopedic implants were also reduced.

Source: Web